Press Releases

Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI

18. May 2023

Johnson & Johnson Completes Acquisition of Abiomed

22. Dec 2022

Learn More

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

21. Dec 2022

First Patients in the World Treated with Impella RP Flex with SmartAssist

06. Dec 2022

Johnson & Johnson to Acquire Abiomed

01. Nov 2022

Learn More

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

21. Oct 2022

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

13. Oct 2022

Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

20. Sep 2022

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

19. Sep 2022

Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

17. Sep 2022

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

19. Aug 2022

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

19. May 2022

World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

26. Apr 2022

First Patient in Japan Treated with Impella 5.5® with SmartAssist®

06. Apr 2022

Regulators Approve Impella 5.5® with SmartAssist® in Japan and Hong Kong; US FDA Grants Impella BTR® Conditional IDE Approval for First-in-Human Early Feasibility Study

19. Jan 2022

Press Releases

Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI

Johnson & Johnson Completes Acquisition of Abiomed

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

First Patients in the World Treated with Impella RP Flex with SmartAssist

Johnson & Johnson to Acquire Abiomed

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

First Patient in Japan Treated with Impella 5.5® with SmartAssist®

Regulators Approve Impella 5.5® with SmartAssist® in Japan and Hong Kong; US FDA Grants Impella BTR® Conditional IDE Approval for First-in-Human Early Feasibility Study

The Protected PCI community is now on HeartRecovery.com

The Protected PCI community
is now on HeartRecovery.com